Impact of timing and dosing of four‐factor prothrombin complex concentrate administration on outcomes in warfarin‐associated intracranial hemorrhage

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy Pub Date : 2022-04-06 DOI:10.1002/phar.2680

Corey D Cicci, A. Weiss, C. Dang, M. Stanton, R. Feldman

引用次数: 2

Abstract

The objective of this study was to evaluate clinical outcomes associated with time to administration and dose of four‐factor prothrombin complex concentrate (4F‐PCC) in patients with ICH on warfarin.

查看原文本刊更多论文

四因子凝血酶原浓缩物给药的时间和剂量对华法林相关颅内出血结局的影响

本研究的目的是评估使用华法林治疗脑出血患者的四因子凝血酶原复合物浓缩物(4F - PCC)与给药时间和剂量相关的临床结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

自引率

0.00%

发文量